Ehrlich, M. I., Fox, R. D., Runcie, K. D., Stein, M. N., & Wei, A. Z. (2025). Novel Strategies and Therapeutic Advances for Bladder Cancer. Cancers, 17(13), 2070. https://doi.org/10.3390/cancers17132070

Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J. A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. (2025). Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339. https://doi.org/10.1016/j.canlet.2024.217339

Plumber, S. A., Tate, T., Al-Ahmadie, H., Chen, X., Choi, W., Basar, M., Lu, C., Viny, A., Batourina, E., Li, J., Gretarsson, K., Alija, B., Molotkov, A., Wiessner, G., Lee, B. H. L., McKiernan, J., McConkey, D. J., Dinney, C., Czerniak, B., & Mendelsohn, C. L. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50678-2

Oliver-Krasinski, J. M., Bidot, S., Ingram, J. W., O’Toole, K. M., McKiernan, J. M., Tinsley, M., & Harik, L. R. (2023). Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features. Archives of Pathology & Laboratory Medicine, 148(2), 223–229. https://doi.org/10.5858/arpa.2022-0268-oa

Farah, O. K., Wang, C. N., & Chung, D. E. (2023). The role of facebook support groups for women with benign urologic conditions. Neurourology and Urodynamics, 42(8), 1795–1801. Portico. https://doi.org/10.1002/nau.25283

Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer, 187, 58–64. https://doi.org/10.1016/j.ejca.2023.03.037

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551

Chen, Z., Tang, X., Christin, J. R., Gao, S. P., Chu, C. E., Berger, M. F., Schultz, N. D., Shen, M. M., Al-Ahmadie, H. A., Iyer, G., Kim, K., & Solit, D. B. (2022). HER2 as a therapeutic target in bladder cancer. European Journal of Cancer, 174, S10–S11. https://doi.org/10.1016/s0959-8049(22)00829-2

Gilbert, N. M., O’Brien, V. P., Waller, C., Batourina, E., Mendelsohn, C. L., & Lewis, A. L. (2022). Gardnerella Exposures Alter Bladder Gene Expression and Augment Uropathogenic Escherichia coli Urinary Tract Infection in Mice. Frontiers in Cellular and Infection Microbiology, 12. https://doi.org/10.3389/fcimb.2022.909799

Rouanne, M., Adam, J., Radulescu, C., Letourneur, D., Bredel, D., Mouraud, S., Goubet, A.-G., Leduc, M., Chen, N., Tan, T. Z., Signolle, N., Bigorgne, A., Dussiot, M., Tselikas, L., Susini, S., Danlos, F.-X., Schneider, A. K., Chabanon, R., Vacher, S., … Marabelle, A. (2022). BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 132(12). https://doi.org/10.1172/jci145666

Tate, T., Xiang, T., Wobker, S. E., Zhou, M., Chen, X., Kim, H., Batourina, E., Lin, C.-S., Kim, W. Y., Lu, C., Mckiernan, J. M., & Mendelsohn, C. L. (2021). Pparg signaling controls bladder cancer subtype and immune exclusion. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-26421-6

Park, S., Rong, L., Owczarek, T. B., Bernardo, M. D., Shoulson, R. L., Chua, C.-W., Kim, J. Y., Lankarani, A., Chakrapani, P., Syed, T., McKiernan, J. M., Solit, D. B., Shen, M. M., Al-Ahmadie, H. A., & Abate-Shen, C. (2021). Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. Cancer Research, 81(20), 5161–5175. https://doi.org/10.1158/0008-5472.can-21-1254

Spigel, D. R., Akerley, W., Evangelist, M., Johnson, M., Levy, B., Owonikoko, T., Paik, P., Papagiannakopoulos, T., Reckamp, K., Akella, L., Holland, S., Jenkins, Y., Kuriakose, E., & Rizvi, N. (2021). P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC. Journal of Thoracic Oncology, 16(10), S1099. https://doi.org/10.1016/j.jtho.2021.08.500

Catenacci, D. V., Liao, C.-Y., Maron, S., Solomon, B. J., Mahipal, A., Johnson, M. L., Carbone, D., Henick, B. S., Johnson, B., Roychowdhury, S., Mody, K., Ahn, D. H., Bournazou, E., Schenk, D., Kounlavouth, S., Kraemer, L., Talbot, G., Rousseau, R., Ferguson, A. R., & Spira, A. (2021). 960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC. Annals of Oncology, 32, S830–S831. https://doi.org/10.1016/j.annonc.2021.08.1345